Destiny Pharma
Skip to content
  • Home
  • About Us
    • Strategy
    • Board of Directors
    • Leadership
    • Scientific Advisory Board
    • History
  • Our Science
    • XF Platform
    • SPOR-COV COVID-19
  • Unmet Need
    • Post Surgical Infections
    • Dermal Infections
    • Other anti-microbial markets
    • COVID-19
  • Pipeline
    • XF-73 Nasal
    • XF-73 Dermal
    • Research Programs
  • Business Development
  • News
  • Investors
    • AIM Rule 26
    • Corporate Governance
    • Share Price Information
    • Regulatory News
    • Constitutional Documents
    • Reports & Presentations
    • Advisers / Shareholder Contacts
    • Analyst Coverage
    • Email Alerts
  • Contact
    • Careers
    • Useful Links

Archive 2012

2012
  • - 17 Oct 2012 – National Institutes of Health launch US clinical trial of XF-73, a new anti-Staphylococcal drug
  • - 01 Jul 2012 – Generating Antibiotic Incentives Now (GAIN) Act passed by US Senate on 26th June 2012
  • - 26 Mar 2012 – Press Release: IND opens for anti-Staphylococcal drug XF-73 and NIAID-funded US clinical trial begins

Archive

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

Destiny Pharma

© All rights reserved.

Powered by WordPress

Destiny Pharma plc
Sussex Innovation Centre
Science Park Square
Brighton
BN1 9SB
UK

Tel: +44(0) 1273 704440

Registered Company
No. 3167025
Home
About Us
Our Science
Unmet Need
Pipeline
Business Development
News
Investors
Contact
Terms of Use
Privacy Statement